ArisGlobal Insights:

Interview with Emmanuel Belabe

Associate Vice President, Safety

This is the second in a four-part blog series that examines the Clinical, Medical Affairs, Regulatory, and Safety product domains at ArisGlobal.

Entering his 16th year with ArisGlobal, Emmanuel “Manny” Belabe serves as Associate Vice President, Safety. In this role, Manny oversees an end-to-end suite of next-generation pharmacovigilance solutions, including LifeSphere MultiVigilance, LifeSphere LitPro and LifeSphere Signal and Risk Management. An ArisGlobal veteran, Manny has been instrumental in the development of the LifeSphere platform, and recently spoke in depth on the vision for LifeSphere Safety for 2020 and beyond.

A lot of work has gone into the development of the LifeSphere Safety platform and particularly LifeSphere MultiVigilance. Where does the platform stand today and what are the priorities for 2020?

With LifeSphere Safety, our mission is to deliver a truly integrated, end-to-end pharmacovigilance platform for the life sciences industry, and you can see how this has come to fruition in our current offerings and product roadmap. What we’ve done, first with ARISg for 30 years, and in 2020 with the all-new LifeSphere MultiVigilance Version 10 (LSMV10), is remarkable to see. As good as ARISg was, LSMV10 has been built from the ground up on next-generation technology and truly represents a step-change in the value that PV departments can get out of a safety system. LSMV10 has actually surpassed our expectations around the benefits that automation technologies like machine learning and natural language processing can bring to case processing.

We’ve been fortunate to work very closely with some of the industry’s top organizations to develop LSMV10 and are proud to see the solution now commercially available. For 2020, we remain focused on helping our customers adopt a practical approach to automation and AI, in a way that’s proven to deliver tangible results and ROI. We understand that there’s a lot of “noise” in the market right now regarding AI and we want to ensure that customers are introduced to automation the right way.

When you say, “ensuring customers are introduced to automation the right way,” what does that mean?

If you look across various industries, there’s a pretty predictable cycle to the adoption of automation technology, or artificial intelligence as its frequently referred to. It usually starts with a lot of hype around the potential of AI and many solution providers claiming to deliver fairly unrealistic productivity gains. This has created skepticism around the practical benefits of automation. With LSMV10, we took the approach of building our solution in direct partnership with large, global life sciences organizations, which allowed us to develop and thoroughly test real world automation use cases. This was a painstaking process, but the result is automation purpose-built from the ground up for pharmacovigilance teams that’s ready on day one. I’d contrast this with a less effective approach that we’ve seen other software providers pursue, which involves trying to apply off the shelf technologies like robotic process automation to PV use cases. We’ve seen and heard from customers that the bottom-up approach we’re taking is much more favorable.

You mentioned building LSMV10 in partnership with ArisGlobal’s customers. Can you talk more about this?

We are very hands-on with our clients. We know that by having our Product Managers interact directly and participate in customer engagements, we can remain close to the pulse of the industry. We’re able to take the feedback and lessons learned from those experiences, and incorporate them directly into our roadmap, which results in products that truly meet the needs of the market.

We deliver a mix of not only technological innovation but practical innovation. This includes a focus on improving our client’s efficiency and the return on investment realized using an ArisGlobal solution. We have seen other companies make claims around machine learning, natural language processing, and dynamic screens which adapt to the data entry process. These are all great initiatives, but the key is combining innovative technology with an ability to offer deep subject matter expertise and a product that reflects direct input from the industry. Just applying technology alone does not guarantee that success. We’re proud to have devoted a significant amount of time to bringing our customers together to align on things like industry standards for out-of-the-box configurations, automation priorities and business rules.

To learn more about LifeSphere® Safety and how we’re delivering the next generation of pharmacovigilance and risk management software, view our webcast “Automation in Pharmacovigilance: From Hype to Reality”.

Request a Demo